Lessee, Operating Lease, Liability, to be Paid, Year Four of Enlivex Therapeutics Ltd. from 31 Dec 2020 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary: Enlivex Therapeutics Ltd. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Four in USD history and change rate from 31 Dec 2020 to 31 Dec 2024.
Enlivex Therapeutics Ltd. Lessee, Operating Lease, Liability, to be Paid, Year Four for the quarter ending 31 Dec 2024 was $88,000, a 27% decline year-over-year.
Source SEC data: View on sec.gov

Lessee, Operating Lease, Liability, to be Paid, Year Four, Quarterly (USD)

Lessee, Operating Lease, Liability, to be Paid, Year Four, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Four (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$88,000	-$33,000	-27%	31 Dec 2024	20-F	30 Apr 2025	2024	FY
Q2 2024	$89,000			30 Jun 2024	6-K	30 Aug 2024	2024	Q2
Q4 2023	$121,000	-$486,000	-80%	31 Dec 2023	20-F	30 Apr 2024	2023	FY
Q4 2022	$607,000	-$226,000	-27%	31 Dec 2022	20-F	10 Apr 2023	2022	FY
Q2 2022	$581,000			30 Jun 2022	6-K	01 Sep 2023	2023	Q2
Q4 2021	$833,000	+$651,000	+358%	31 Dec 2021	20-F	29 Apr 2022	2021	FY
Q4 2020	$182,000			31 Dec 2020	20-F	30 Apr 2021	2020	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.